



Evidence synthesis services
The value is in the data



The growth in the availability of both data and literature is evident. The popularisation of research and the global ease of access through the internet has increased the amount of published peer-reviewed journals and articles. Moreover, the number of clinical trials submitted for registration in clinicaltrials.gov has increased from 49,000 in 2007 to over 188,000 at present! Identifying and gathering all data available can be quite overwhelming and it is essential that only the most appropriate information is used.

- Do you keep pace with this overload of scientific knowledge?
- Are all of your decisions well informed?
- Are you aware of the latest developments in your product categories?
- Do you know all about your competing products and the endpoints they have used?
- Do you want to enhance your product's value proposition?

If you are unclear about one or more of these questions, the Deloitte's Evidence Synthesis services may be able to help you.

The Deloitte HEOR centre of excellence

A team of experienced health policy and HEOR professionals is at your service to provide the latest insights in the field of evidence synthesis. Our team has several years of experience in the design and conduction of systematic literature reviews, meta-analyses and mixed treatment comparisons to create an offering tailored to your specific needs.

A brief overview of our evidence synthesis specific offerings

- Grey/systematic literature reviews
- Meta-analyses
- Comparative effectiveness analysis



Inform your decisions Enhance your product value

Grey/systematic literature reviews

A **grey literature review** is a method of collecting data, generally via the internet of literature freely available and is often related to governmental bodies, academics and NGO's. It provides data of high quality (when selected properly) and can give great insights in policy making decisions.

A **systematic literature review** is a strictly framed process to collect, select and appraise a number of studies deemed to answer a particular research question. It generally only uses data from peer-reviewed journals and is therefore of guaranteed high quality. Specific search terms are used in order to only extract the data most relevant to the posted research question.

Why perform a literature review?

- Identify treatment methods and best practices
- Collect evidence for value stories
- Defining/addressing knowledge gaps

Meta-analyses

A meta-analysis is the statistical process for pooling data from multiple studies and it allows to make the best use of all the evidence gathered in a systematic review by increasing the power of the analysis.

Why perform a meta-analysis?

- Quantify treatment effects and their uncertainty
- Increase power and/or precision
- Settle controversies from conflicting studies

Comparative effectiveness analysis

Used to compare different types of interventions showing their individual characteristics. Goal here is to analyse which treatment will have the best outcomes under a specified set of circumstances

Why perform a comparative effectiveness analysis?

- Helps to in the informed decision making process
- Use ICER and CEA to calculate and compare the financial effectiveness of treatments
- Give insights into the benefits and harms of the available treatment options

The benefits of evidence synthesis


By making use of the various evidence synthesis tools you can gather evidence on treatments, applications, costs, safety and much more. Much of this data you can also collect by conducting clinical trials but these are very expensive and time consuming. Our evidence synthesis offering will allow you to compare these treatments and their outcomes in a much more cost effective manner. Basically, you will get evidence collected with a proofed methodology, whilst always considering the latest developments in your specific field.

The Unique offering of Deloitte

Deloitte European health economics and outcomes research group is part of Deloitte's global network of 7,600 Life Sciences and Healthcare practitioners across 76 member firms worldwide. We are able to provide you with the latest insights in the field of market access and health economics using the most innovative research methods available.

ConvergeHEALTH is the data platform of Deloitte is able to complement these insights by making use of their analytics platforms and data models. The data provided by ConvergeHEALTH can give you RWE insights in the application of medical treatments and combining this with the offering of the health economics and outcomes research group will give you insights no other firm can provide.

ConvergeHEALTH
by **Deloitte**.



Contacts

For more information, please contact:

Ömer Saka MD, MSc

Partner

Health Economics and
Outcomes Research Group

T: +32 2 749 57 32

M: +32 473 33 54 27

rsaka@deloitte.com

Edith Maes, DBA, MHSM

Director

Health Economics and
Outcomes Research Group

T: + 32 2 600 62 42

M: 32 471 63 60 96

emaes@deloitte.com

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. Please see www.deloitte.com/about for a more detailed description of DTTL and its member firms.

Deloitte provides audit, tax and legal, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte has in the region of 200,000 professionals, all committed to becoming the standard of excellence.

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively, the "Deloitte Network") is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.